happy and healthy family


Enanta applies its chemistry-driven approach and drug discovery capabilities to developing small molecule cures for viral infections and liver diseases impacting the highest at-risk patient populations. Long before the SARS-CoV-2 pandemic engulfed the world, Enanta always believed that the most profoundly beneficial impact to improve health is to address long-standing gaps in drug development R&D that have inadequately addressed the prevention and treatment of infectious diseases. Enanta’s commitment to ‘reach high’ on behalf of the most at-risk patients has been unyielding. Through our collaboration with AbbVie, we helped discover two cures for hepatitis C and today have novel, potential cures under development for infections of respiratory syncytial virus, SARS-CoV-2 and hepatitis B virus. At Enanta, we are building a leading treatment portfolio for viral respiratory infections. To learn more about participation in Enanta clinical trials, please see below.

Clinical Trials

Enanta is committed to the development of novel treatments for viral infections and liver diseases for patients with serious medical conditions. Enanta has active clinical trial programs in respiratory syncytial virus (RSV) and SARS-CoV-2 (COVID-19).

If you are interested in learning more about Enanta’s current and future clinical trials, please contact:

Through clinical trials we are advancing novel therapeutics for significant respiratory infections.

Respiratory Syncytial Virus


Read More »

SPRINT (SARS-Cov-2 PRotease INhibitor Treatment)

Therapeutic: EDP-235, in development as a potential treatment for COVID-19

Trial Status: Actively recruiting

Trial Information: SPRINT is a Phase 2 randomized, double-blind, placebo-controlled study enrolling approximately 200 non-hospitalized, symptomatic patients, aged 18 to 64, with mild to moderate COVID-19, who are not at increased risk for developing severe disease. To be included in the study patients must have tested positive for SARS-CoV-2 by PCR or rapid antigen test with a confirmed test within 24 hours before enrollment, had symptoms for five days or less and have not received a SARS-CoV-2 vaccine dose less than 90 days before enrollment and/or been infected with SARS-CoV-2 less than90 days of enrollment.

Patients will receive EDP-235 orally at a dose of 200mg or 400mg or placebo once daily for five days. The primary objective of the study is to evaluate the safety and tolerability of EDP-235. Secondary objectives include the evaluation of virologic endpoints, clinical symptoms and outcomes, and pharmacokinetics

Patient Resources

Respiratory Syncytial Virus (RSV)

American Lung Association logo
American Thoracic logo
CDC logo
healthy children dot org logo
National Foundation for Infectious Diseases logo


CDC logo
Johns Hopkins University logo

Hepatitis B Virus (HBV)

CDC logo
Hepatits B Foundation logo
Hep B United dot org logo
World Hepatitis Alliance logo

Human Metapneumovirus (hMPV)

American Lung Association logo
CDC logo